1.
Ophthalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502.
Grochowicki M, Khalfallah Y, Vighetto A, Berquet S, Sassolas G
Br J OphthalmolDec 19933 citationsCase Series
This study found the prolactin inhibitor CV 205-502 effectively improved or stabilized visual function in macroprolactinoma patients, demonstrating its clinical utility in preserving vision affected by these tumors.